berlin. A groundbreaking case has emerged from Zagreb, where virologist Beata Halassy reportedly injected herself with self-cultivated viruses to combat her breast cancer. Over two months, the treatment led to a significant reduction in tumor size, allowing for prosperous surgical removal.Halassy claims to have been cancer-free for 45 months, citing positive short- and medium-term results in her report published in the scientific journal Vaccines. This unconventional approach has sparked intense debate within the medical community regarding ethical standards and the potential impact on conventional cancer treatments.
In a groundbreaking approach to cancer treatment, virologist Beata Halassy has turned to a self-administered therapy involving engineered viruses to combat her recurring breast cancer. After enduring multiple rounds of chemotherapy and a mastectomy, Halassy injects a cultivated strain of the measles virus followed by a stomatitis virus directly into her tumor. This unconventional method is rooted in oncolytic virotherapy, a field of research that has explored the potential of viruses to selectively target and destroy cancer cells sence the 1970s. While Halassy’s self-treatment raises eyebrows, it is indeed conducted under the supervision of oncologists who are prepared to intervene if necessary, highlighting the ongoing quest for innovative cancer therapies.A groundbreaking treatment for advanced melanoma, derived from a herpes virus, has gained approval in both the United States and Europe since its introduction in 2015. this innovative therapy has shown significant promise, with numerous oncologists reporting successful local applications in their practices. Professor Guy Ungerechts, a prominent cancer researcher and Deputy Medical Director at the National Center for tumor Diseases in Heidelberg, emphasizes the wealth of experience accumulated with this medication, highlighting its effectiveness in stimulating the immune system to target and destroy cancer cells. As research continues to evolve, this treatment represents a significant advancement in the fight against one of the most aggressive forms of skin cancer.in a groundbreaking approach to cancer treatment, renowned researcher Guy Ungerechts supports a controversial healing attempt led by virologist beata Halassy. This experimental method, which utilizes specific viruses known to target and destroy cancer cells, is deemed acceptable only under strict conditions: patients must have no other treatment options and must be fully informed of the potential risks, including fatal outcomes.Ungerechts emphasizes the importance of clarity and consensus among medical professionals to prevent misinformation that could mislead patients into believing in a miracle cure. His research,spanning nearly two decades,focuses on viruses like measles and herpes that can effectively attack cancer cells,highlighting a promising yet cautious path in the fight against cancer.A Croatian researcher has achieved remarkable success in her battle against breast cancer by utilizing modified measles and stomatitis viruses, remaining cancer-free for over 45 months. This innovative approach is part of a broader trend in cancer treatment, where oncolytic virus therapy (OVT) is being explored as a promising immunotherapy. In Heidelberg, preparations are underway for a clinical study aimed at developing a new OVT based on measles virus, with hopes of gaining regulatory approval in Europe. Experts believe that these engineered viruses could significantly enhance treatment outcomes for solid tumors and metastatic cancers, marking a potential breakthrough in oncology.Innovative cancer treatments are on the horizon,with experts predicting significant advancements in the next five to ten years. Dr. Ungerechts emphasizes the potential for new medications to offer highly personalized therapies that could transform the management of metastatic cancer, potentially allowing patients to live with their condition as a chronic illness. While the use of oncolytic viruses in self-medication is not recommended as a primary treatment, researchers like Beata Halassy advocate for increased funding and support for this promising area of study. As the landscape of cancer treatment evolves, the focus remains on developing effective, individualized options that complement conventional therapies.